TSHA
Taysha Gene Therapies, Inc. (NASDAQ)
Healthcare — Biotechnology
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Price History
Fundamentals
| Market Cap | $1.90B |
| P/E Ratio (TTM) | - |
| Forward P/E | -15.20 |
| EPS (TTM) | $-0.38 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -97.28% |
| Debt/Equity | 32.34 |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $13.00 |
| Analysts | 13 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 66.5 |
| Beta | 1.18 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.30 |
| 52-Week Low | $2.33 |
| 50-Day Avg | $6.16 |
| 200-Day Avg | $5.02 |
| Avg Volume | $3.04M |
| Volume | $1.62M |
Performance Analysis
BULLISHTSHA shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:35 UTC
Back to Screener Export Report